On April 20, Maccura Biotechnology Co.Ltd(300463) published the annual report of 2021. During the reporting period, the company’s revenue and net profit increased; Nearly 90% of them come from the contribution of the company’s independent products.
Affected by this news, Maccura Biotechnology Co.Ltd(300463) share price on that day was reported at 21.62 yuan / share, slightly down 1.91%, with a total market value of 13.242 billion yuan.
profit growth
According to the data, Maccura Biotechnology Co.Ltd(300463) was listed in May 2015. Its main business is independent research and development, production and sales of in vitro diagnostic products and agent sales of in vitro diagnostic products of foreign well-known brands.
On April 20, Maccura Biotechnology Co.Ltd(300463) published the annual report of 2021. During the reporting period, the company achieved a revenue of 3.981 billion yuan, a year-on-year increase of 7.47%; The net profit attributable to shares was 957 million yuan, a year-on-year increase of 20.49%.
Looking back at the achievements of Maccura Biotechnology Co.Ltd(300463) in the past, from 2018 to 2020, Maccura Biotechnology Co.Ltd(300463) achieved revenue of 2.685 billion, 3.223 billion and 3.704 billion respectively; The net profits were 445 million, 525 million and 794 million respectively. The increase in profits in the past two years has something to do with the epidemic in China.
In terms of business, 86% of Maccura Biotechnology Co.Ltd(300463) net profit during the reporting period came from independent products, which are divided into conventional testing products and covid-19 testing products (belonging to molecular platform). In recent years, Maccura Biotechnology Co.Ltd(300463) independent products have maintained rapid growth and their proportion in sales revenue has increased rapidly.
In 2021, the sales revenue of the company’s independent products was 2.3 billion, with a year-on-year increase of 24.08%, and the sales proportion increased from 50.03% to 57.77%. The New Coronavirus 2019-nCoV nucleic acid detection kit (fluorescent PCR method) in its own products has a revenue of 711 million yuan, an increase of 24.19% over the same period last year. The sales revenue of agency products showed a downward trend, reaching 1.635 billion last year, a year-on-year decrease of 9.76%.
According to the annual report, the revenue of Maccura Biotechnology Co.Ltd(300463) covid-19 testing products in 2021 was 716 million, an increase of 0.93% year-on-year Maccura Biotechnology Co.Ltd(300463) n said that although the company’s covid-19 nucleic acid detection products are mainly distributed, the impact of centralized purchase policy and market competition also makes the price of covid-19 detection products have a downward trend. Due to the advantage of production cost, the gross profit margin of covid-19 test products decreased slightly by 4.63% in 2021.
In addition, during the reporting period, the sales revenue of Maccura Biotechnology Co.Ltd(300463) conventional products was 1.583 billion, a year-on-year increase of 38.45%. Among the conventional reagent products, the sales of immune reagents was 642 million, with a year-on-year increase of 33.42%; The sales of biochemical reagents reached 617 million, with a year-on-year increase of 13.28%; The sales of temporary test reagents reached 92 million, with a year-on-year increase of 42.65%.
In terms of gross profit margin, in 2021, the annual gross profit margin of Maccura Biotechnology Co.Ltd(300463) independent products was 79.09%, while that of agency products was 27.26%. Independent products accounted for 57.77% of the revenue structure and 86% of the profit contribution.
Although the performance of Maccura Biotechnology Co.Ltd(300463) 2021 is generally upward, its “performance” in the fourth quarter can not be ignored.
In 2021, the company’s net profit from equity return was 957 million, while the third quarterly report of 2021 showed that the net profit from equity return in the first three quarters was 796 million. According to the calculation, the net profit from equity return in the fourth quarter of 2021 was only 161 million, which was significantly lower than 228 million yuan in the same period of 2020.
fixed increase fund raising attracted attention
After planning for one and a half years, Maccura Biotechnology Co.Ltd(300463) ‘s fund-raising plan was finally implemented, but the result was unsatisfactory.
As early as August 2020, Maccura Biotechnology Co.Ltd(300463) announced its fixed growth plan Maccura Biotechnology Co.Ltd(300463) plans to raise an additional 2.769 billion yuan, mainly for Maccura Biotechnology Co.Ltd(300463) Tianfu international biological city IVD Industrial Park project, informatization and marketing network construction project, and supplement the company’s working capital. Among them, the project with the largest amount of funds to be invested is the IVD Industrial Park project, and the amount of funds to be raised is 2.059 billion yuan.
According to the information recently disclosed by Maccura Biotechnology Co.Ltd(300463) company, this time Maccura Biotechnology Co.Ltd(300463) issued 56 million non-public shares to 17 specific objects, raising a total of 1.574 billion yuan, about 56.8% of the original plan ceiling. Among them, Gaoyi assets were allocated a total of 270 million yuan and CAITONG fund was allocated 290 million yuan.
With the reduction of the fund-raising scale, the use plan of the raised funds of the above-mentioned projects has also been adjusted, and the scale of the funds to be invested in all projects is nearly halved. The total amount of raised funds to be used for IVD Industrial Park project is reduced to RMB 1.157 billion.
It is worth noting that, as one of the main subscribers of the fixed increase, Gaoyi assets seems to have a special preference for Maccura Biotechnology Co.Ltd(300463) .
It is understood that as early as the first quarter of 2018, Deng Xiaofeng of Gaoyi assets invested 130 million yuan and held 5.2039 million shares. Xinjin became the ninth largest circulating shareholder of Maccura Biotechnology Co.Ltd(300463) . The top ten shareholders of Gaoyi frequently withdrew from the list of assets at the end of the year.
However, it seems that Gao Yi’s asset, which is in love with Maccura Biotechnology Co.Ltd(300463) the company, has overturned this time.
As of March 18, 2022, Gao yixiaofeng No. 2 letter fund held Maccura Biotechnology Co.Ltd(300463) 7114900 shares.
However, due to the poor performance of Maccura Biotechnology Co.Ltd(300463) share price, the shareholding of the issuing object participating in Maccura Biotechnology Co.Ltd(300463) fixed increase has suffered a floating loss. As of the closing on April 20, the closing price of Maccura Biotechnology Co.Ltd(300463) was 21.62 yuan / share, while the issuance price of this fixed increase was 28.11 yuan / share, about 23% higher than the secondary market price. At this price, Gao Yi’s assets have suffered a floating loss of more than 36 million yuan.
